Clinical Perspectives: A Case-Based Discussion of Targeted Therapy in Metastatic Pancreatic Cancer
In this case-based discussion, experts examine the phase 3 RASolute 302 efficacy and safety data for daraxonrasib, an FDA-approved RAS inhibitor for metastatic pancreatic adenocarcinoma (mPDAC). The panelists discuss how to interpret the findings in the evolving treatment landscape and share real-world strategies for managing treatment-related adverse events and supporting patients on treatment.
Round 1
Interpreting Clinical Data for Targeted Therapy in mPDAC
A case involving a patient with a KRAS G12D mutation who progresses after first-line therapy prompts discussion of second-line treatment selection. The panel examines RASolute 302 efficacy findings in the RAS G12 population and provides an overview of the trial’s safety data.
Round 2
The Role of Targeted Therapy in mPDAC and Tolerability Considerations
The panel examines RASolute 302 efficacy findings in the overall study population, then takes a closer look at the safety data, discussing treatment-related adverse events and practical approaches to their recognition and management.
© 2026 HMP Global. All Rights Reserved.
This is a non-CME activity. The views and opinions expressed by the presenter(s) do not necessarily reflect the views and opinions of the Oncology Learning Network, HMP Global, or its employees and affiliates.
